Phase 3 Recruiting NIH
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in Minnesota: - Riverwood Healthcare Center — Aitkin, Minnesota
- Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Fairview Ridges Hospital — Burnsville, Minnesota
- Minnesota Oncology - Burnsville — Burnsville, Minnesota
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Minnesota: - Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota
- Essentia Health Cancer Center — Duluth, Minnesota
- Essentia Health Saint Mary's Medical Center — Duluth, Minnesota
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Minnesota: - USOR - Minnesota Oncology - Burnsville — Burnsville, Minnesota
- Local Institution - 007-589A — Edina, Minnesota
- Local Institution - Unk006 — Minneapolis, Minnesota
- Local Institution - 007-822 — Minneapolis, Minnesota
- Local Institution - 007-830 — Rochester, Minnesota
Phase 3 Recruiting Industry
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…
Sponsor: Pfizer
NCT ID: NCT07222566
Sites in Minnesota: - Minnesota Oncology Hematology, P.A. — Burnsville, Minnesota
- Minnesota Oncology Hematology, P.A. — Chaska, Minnesota
- Minnesota Oncology Hematology, P.A. — Coon Rapids, Minnesota
- Minnesota Oncology Hematology, P.A. — Edina, Minnesota
- Minnesota Oncology Hematology, P.A. — Maple Grove, Minnesota
Phase 3 Recruiting Industry
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …
Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Minnesota: - Allina Health Cancer Institute - Abbott Northwestern Hospital — Minneapolis, Minnesota
- HealthPartners Cancer Research Center — Saint Paul, Minnesota
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in Minnesota: - Clinical Study Site — Minneapolis, Minnesota
- Clinical Study Site — Saint Louis Park, Minnesota
- Clinical Study Site — Saint Paul, Minnesota
Phase 3 Recruiting Industry
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary en…
Sponsor: Summit Therapeutics
NCT ID: NCT05899608
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
- Park Nicollet Institute — Saint Paul, Minnesota
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemot…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07063745
Sites in Minnesota: - Mayo Clinic in Rochester, Minnesota — Rochester, Minnesota
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Phase 3 Recruiting Industry
The purpose of this phase 3 multicenter double-blind randomized study is to assess the use of taletrectinib in the early-stage non-small cell lung cancer (NSCLC). The study compares taletrectinib (study drug) versus placebo (sugar pill) in…
Sponsor: Nuvation Bio Inc.
NCT ID: NCT07154706
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 3 Recruiting Industry
This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging …
Sponsor: Vergent Bioscience, Inc.
NCT ID: NCT07499674
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 2 Recruiting Network
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places i…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06031688
Sites in Minnesota: - Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota
- Essentia Health Cancer Center — Duluth, Minnesota
- Essentia Health Hibbing Clinic — Hibbing, Minnesota
- Essentia Health Sandstone — Sandstone, Minnesota
Phase 2 Recruiting Industry
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-smal…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06667076
Sites in Minnesota: - University Of Minnesota — Minneapolis, Minnesota
- Mayo Clinic Rochester — Rochester, Minnesota
Phase 2 Recruiting Industry
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT04614103
Sites in Minnesota: - University of Minnesota — Minneapolis, Minnesota
Phase 2 Recruiting Industry
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1/PD-1 …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06095505
Sites in Minnesota: - Minnesota Oncology Hematology — Burnsville, Minnesota
Phase 1, Phase 2 Recruiting Industry
This Phase1/2, open label, multicenter study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with NSCLC having EGFR and/or HER2 mutations. Phase 1 wi…
Sponsor: BlossomHill Therapeutics
NCT ID: NCT06706076
Sites in Minnesota: - Mayo Clinic Hospital - Rochester, MN — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06922591
Sites in Minnesota: - Mayo Clinic Cancer Center — Rochester, Minnesota
Phase 2 Recruiting Industry
This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this stud…
Sponsor: Boehringer Ingelheim
NCT ID: NCT05882058
Sites in Minnesota: - Mayo Clinic, Rochester — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…
Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Minnesota: - Mayo Rochester — Rochester, Minnesota
Phase 2 Recruiting Academic/Other
A randomized trial of adjuvant Pembrolizumab following surgical resection versus observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm. Patients will be rand…
Sponsor: Greg Durm, MD
NCT ID: NCT04317534
Sites in Minnesota: - University of Minnesota — Minneapolis, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered eithe…
Sponsor: Aulos Bioscience, Inc.
NCT ID: NCT05267626
Sites in Minnesota: - Minnesota Oncology and Hematology PA — Minneapolis, Minnesota
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
Sponsor: AstraZeneca
NCT ID: NCT06996782
Sites in Minnesota: - Research Site — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Minnesota: - Masonic Cancer Center University of Minnesota — Minneapolis, Minnesota
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to rem…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07428044
Sites in Minnesota: - Mayo Clinic (Data Collection Only) — Rochester, Minnesota